Xenetic Biosciences Inc. (XBIO) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, XBIO scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6 / 20, reflecting ROIC of -30.3% and an FCF yield of 0%; Whale 13F Flow at 5 / 20, covering institutional accumulation and options positioning; Insider Conviction at 5 / 20, covering SEC Form 4 and Congressional PTR cluster flow; Macro Regime Fit at 7 / 20, reflecting Beta of 1.0 and sector sensitivity; and Forensic Balance Sheet at 11 / 20, reflecting Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.5. For a prospective investor, the weakest pillars are the cash engine and the ownership-flow signals, both of which sit at or near the bottom of their ranges. The strongest pillar, balance sheet, is still only 11 of 20. Per the Roarable RQD rating, the overall picture is one of forensic risk rather than an identifiable upside driver, so the rating points toward caution on valuation and on the durability of the business model rather than toward any near-term return thesis.

Per the SEC financials, the company reported operating losses in each of the three periods, with operating income of $-2.8M in FY 2025, $-4.2M in FY 2024, and $-4.5M in FY 2023. Per the market data, operating margin is -60%, net margin is -60%, and gross margin is 0%, with ROIC at -30.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash and debt balances are not available in source data for any period.

Per the recent news feed, the most prominent item is an announcement that Xenetic Biosciences and PeriNess reported a first patient dosed in an investigator-initiated study at Tel Aviv Sourasky University Medical Center evaluating systemic DNase in combination with CAR T cells for large B-cell lymphoma. This is the single company-specific catalyst in the feed. The remaining five items are Yahoo-family market pages for XBIO and other tickers (DARE, VTVT, JUNS) with generic descriptions and no company-specific fundamental content, so they carry limited analytical weight. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Risk watch items drawn from the data include continued operating losses, the sub-$5M market capitalization, and a 52-week range spanning $1.58 to $4.94.

• What are the company's cash and debt balances in each reported period, given that these fields are N/A throughout the financials?
• What share count and EPS figures support the $5.0M market capitalization and the reported net losses?
• What is the revenue source behind the reported $2.5M to $3.0M in annual revenue, and how does it relate to the pharmaceutical development activity described in the catalyst?
• What is the timing, scope, and funding runway of the investigator-initiated study, and does it have any financial disclosure attached?
• What institutional, insider, or congressional holdings exist, given that the holders section is empty?